January 6, 2025 10:00 AM EST

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

ENDPOINTS

2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Solid Bio's former CEO launches new rare disease startup with €65M Series A

FDA sets an efficacy threshold for future weight loss drugs

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line